Literature DB >> 9203047

Plasma erythropoietin level and iron reserves in haemodialysis patients with and without acquired cystic kidney disease.

M Majdan1, A Ksiazek, M Kozioł, D Spasiewicz.   

Abstract

Concentration of erythropoietin (Epo) and iron reserves (IR) belong to the essential factors determining erythropoiesis in haemodialysis patients. Patients on dialysis with acquired kidney disease (ACKD+) can control anaemia better than patients without acquired kidney disease (ACKD-). Therefore we decided to check if plasma Epo levels and IR differ significantly in both groups of patients. Forty chronically haemodialyzed patients after ultrasound diagnosis were divided into 18 patients (45%) with ACKD+ and 22 (55%) without ACKD-. In both groups of patients we compared their plasma levels of Epo and IR. Plasma erythropoietin and ferritin levels were measured by enzymatic immunoassay. Iron reserves were estimated by the formula: IR = 400 x [ln (ferritin)-ln (50)]. In the ACKD+ group 72% of patients and in the ACKD- group 32% of patients did not require rHu Epo therapy. Plasma levels of erythropoietin and iron reserves did not differ significantly between ACKD+ and ACKD- patients. There must be also other factors than erythropoietin levels and iron reserves regulating erythropoiesis in these patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203047     DOI: 10.1007/bf02551426

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  13 in total

Review 1.  The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin.

Authors:  J W Eschbach
Journal:  Kidney Int       Date:  1989-01       Impact factor: 10.612

2.  Clinical characteristics and diagnostic considerations in acquired renal cystic disease.

Authors:  N Narasimhan; T A Golper; M Wolfson; M Rahatzad; W M Bennett
Journal:  Kidney Int       Date:  1986-11       Impact factor: 10.612

3.  Monitoring of iron requirements in renal patients on erythropoietin.

Authors:  E G Anastassiades; D Howarth; J Howarth; D Shanks; H M Waters; K Hyde; C G Geary; J A Yin; R Gokal
Journal:  Nephrol Dial Transplant       Date:  1993       Impact factor: 5.992

Review 4.  Hereditary and acquired cystic disease of the kidney.

Authors:  G M Fick; P A Gabow
Journal:  Kidney Int       Date:  1994-10       Impact factor: 10.612

5.  Erythropoiesis in dialysis patients with acquired cystic kidney disease. Collaborative Group of Nephrologists of the East of France.

Authors:  F Schillinger
Journal:  Nephron       Date:  1994       Impact factor: 2.847

6.  Acquired cystic disease of the kidneys: a hazard of long-term intermittent maintenance haemodialysis.

Authors:  M S Dunnill; P R Millard; D Oliver
Journal:  J Clin Pathol       Date:  1977-09       Impact factor: 3.411

7.  Anemia in dialysis: its relation to acquired cystic kidney disease and serum levels of erythropoietin.

Authors:  A Férnandez; L Hortal; J C Rodríguez; N Vega; C Plaza; L Palop
Journal:  Am J Nephrol       Date:  1991       Impact factor: 3.754

8.  Serum erythropoietin concentrations and iron status in patients on chronic hemodialysis.

Authors:  C Seguchi; T Shima; M Misaki; Y Takarada; T Okazaki
Journal:  Clin Chem       Date:  1992-02       Impact factor: 8.327

9.  [Comparison of clinical parameters of chronically hemodialyzed patients not requiring treatment with erythropoietin and patients treated with erythropoietin].

Authors:  M Majdan; A Ksiazek; A Swatowski; G Sokołowska; I Bartler
Journal:  Pol Arch Med Wewn       Date:  1994-06

10.  The N-terminal sequence of the major erythropoietic factor of an anephric patient is identical to insulin-like growth factor I.

Authors:  L F Congote; A Brox; F K Lin; H S Lu; A A Fauser
Journal:  J Clin Endocrinol Metab       Date:  1991-03       Impact factor: 5.958

View more
  1 in total

1.  Changes of endogenous erythropoietin level and iron status during a 30-month hemodialysis treatment of a group of patients.

Authors:  M Majdan; A Ksiazek; A Bednarek-Skublewska; D Spasiewicz
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.